TTY Biopharm Co (ROCO:4105) EV-to-Revenue : 3.30 (As of Apr. 27, 2024)

View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, TTY Biopharm Co's enterprise value is NT$18,145 Mil. TTY Biopharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$5,506 Mil. Therefore, TTY Biopharm Co's EV-to-Revenue for today is 3.30.

The historical rank and industry rank for TTY Biopharm Co's EV-to-Revenue or its related term are showing as below:

ROCO:4105' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.18 Med: 4.93 Max: 10.54
Current: 3.3

During the past 13 years, the highest EV-to-Revenue of TTY Biopharm Co was 10.54. The lowest was 3.18. And the median was 4.93.

ROCO:4105's EV-to-Revenue is ranked worse than
64.81% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs ROCO:4105: 3.30

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), TTY Biopharm Co's stock price is NT$76.60. TTY Biopharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$22.10. Therefore, TTY Biopharm Co's PS Ratio for today is 3.47.

TTY Biopharm Co EV-to-Revenue Historical Data

The historical data trend for TTY Biopharm Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co EV-to-Revenue Chart

TTY Biopharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.42

4.09

3.82

4.05

3.57

TTY Biopharm Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															4.05	3.56	3.72	3.58	3.57

Competitive Comparison of TTY Biopharm Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TTY Biopharm Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where TTY Biopharm Co's EV-to-Revenue falls into.

TTY Biopharm Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

TTY Biopharm Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	18145.077	/	5505.542
	=	3.30

TTY Biopharm Co's current Enterprise Value is NT$18,145 Mil.
TTY Biopharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5,506 Mil.

TTY Biopharm Co (ROCO:4105) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

TTY Biopharm Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	76.60	/	22.096
	=	3.47

TTY Biopharm Co's share price for today is NT$76.60.
TTY Biopharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.10.

TTY Biopharm Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of TTY Biopharm Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TTY Biopharm Co (ROCO:4105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503

Website

https://www.tty.com.tw

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segment includes Oncology, Health Care, Anti-Infection, Domestic Cardiovascular and Gastrointestinal Drugs, and other segments. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co (ROCO:4105) Headlines

No Headlines